Enorama Pharma AB (publ)
ERMA.ST
Get informed when a big investor buys or sells
+ FollowMarket Cap$46.84M
Close$
$-0.07
111% downside
Current Fair Value
111% downsideOvervalued by 111% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $46.84 Million |
|---|---|
| Enterprise Value | $44.74 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.08 |
| Beta | 1.8 |
| Outstanding Shares | 74,588,682 |
Return
| Return on Equity | 118.31% |
|---|---|
| Return on Assets | -858.46% |
| Return on Invested Capital | 211.27% |
Valuation & Multiples
| P/E Ratio | -0.78 |
|---|---|
| PEG | 2.59 |
| Price to Sales | - |
| Price to Book Ratio | -0.63 |
| Enterprise Value to Revenue | 30.9 |
| Enterprise Value to EBIT | -0.82 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Enorama Pharma AB (publ)
4 employees
CEO: Bengt Jönsson Enorama Pharma AB (publ), a pharmaceutical company, develops, manufactures, and sells medicated chewing gum in Sweden. It offers nicotine chewing gum and nicotine pouches under the NIC-S brand name. The company was incorporated in 2006 and is based in Malmö, Sweden.